Sanofi's amlitelimab shows positive results in atopic dermatitis trials

March 28, 2026 11:00 AM

Sanofi (EURONEXT: SAN) (NASDAQ: SNY) presented positive results from three phase 3 studies of amlitelimab for moderate-to-severe atopic dermatitis at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found